Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice

Ajeet Gajra, Abigail Zalenski, Aishwarya Sannareddy, Yolaine Jeune-Smith, Kandice Kapinos, Ankit Kansagra

Research output: Contribution to journalArticlepeer-review

Abstract

Chimeric antigen receptor T-cell (CAR-T) therapy is a revolutionary cancer treatment modality where a patient’s own T cells are collected and engineered ex vivo to express a chimeric antigen receptor (CAR). These reprogrammed CAR-T cells, when reinfused into the same patient, stimulate a T-cell mediated immune response against the antigen-expressing malignant cells leading to cell death. The initial results from pivotal clinical trials of CAR-T agents have been promising, leading to multiple approvals in various hematologic malignancies in the relapsed setting, including acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma, follicular lymphoma, and, more recently, multiple myeloma. However, since the initial trials and US Food and Drug Administration approvals, there have been significant barriers to the widespread use of this therapy. The barriers to the use of CAR-T therapy include complex logistics, manufacturing limitations, toxicity concerns, and financial burden. This review discusses potential solutions to overcome these barriers in order to make this life-changing therapy widely accessible.

Original languageEnglish (US)
Pages (from-to)163-171
Number of pages9
JournalPharmaceutical Medicine
Volume36
Issue number3
DOIs
StatePublished - Jun 2022

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice'. Together they form a unique fingerprint.

Cite this